CAR-T Meeting 2024 | The future of cord blood-derived NK cells and how their persistence can be improved
Beatriz Martin Antonio, PhD, Fundación Jimenez Diaz, Madrid, Spain, comments on the future of cord blood-derived natural killer (NK) cells in hematological malignancies. Several clinical trials have demonstrated the safety of NK and CAR NK cells; however, progress is required to enhance their persistence and efficacy. Some current approaches involve combining them with cytokine or antibody administration. When investigating NK cells, it must be taken into consideration that they will have a greater efficacy in malignancies in which human leukocyte antigen (HLA) downregulation occurs. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
